Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: Where are we now in the era of the next generation proteomics?

Jong-Min Park, Na Young Han, Young-Min Han, Mi Kyung Chung, Hoo Keun Lee, Kwang Hyun Ko, Eun-Hee Kim, Ki Baik Hahm

Jong-Min Park, Young-Min Han, Mi Kyung Chung, Eun-Hee Kim, Ki Baik Hahm, CHA Cancer Prevention Research Center, CHA University, Seoul 135-081, South Korea

Na Young Han, Hoo Keun Lee, Gachon University College of Pharmacy, Incheon 406-799, South Korea

Kwang Hyun Ko, Ki Baik Hahm, Digestive Disease Center, CHA University Bundang Medical Center, Seongnam 463-838, South Korea

Author contributions: Park JM and Han NY contributed equally to this manuscript; Park JM and Han NY performed the majority of the experiments; Han YM, Chung MK and Ko KH contributed new reagents or analytic tools; Lee HK, Kim EH, and Hahm KB designed the study; Park JM and Hahm KB analyzed the data and wrote the manuscript.

Supported by Grant from the Ministry of Education and Science Technology, 2010-0002052, Korea and JSPS Asian CORE Program, Japan

Correspondence to: Ki Baik Hahm, MD, PhD, Professor, CHA Cancer Prevention Research Center, CHA University, 605 Yeoksam 1-dong, Gangnam-gu, Seoul 135-081, South Korea. hahmkb@cha.ac.kr

Telephone: +82-2-34682869 Fax: +82-2-34682868

Received: December 27, 2013 Revised: March 10, 2014 Accepted: June 14, 2014

Abstract

Recent advances in genomic medicine have opened up the possibility of tailored medicine that may eventually replace traditional “one-size-fits all” approaches to the treatment of inflammatory bowel disease (IBD). In addition to exploring the interactions between hosts and microbes, referred to as the microbiome, a variety of strategies that can be tailored to an individual in the coming era of personalized medicine in the treatment of IBD are being investigated. These include prompt genomic screening of patients at risk of developing IBD, the utility of molecular discrimination of IBD subtypes among patients diagnosed with IBD, and the discovery of proteome biomarkers to diagnose or predict cancer risks. Host genetic factors influence the etiology of IBD, as do microbial ecosystems in the human bowel, which are not uniform, but instead represent many different microhabitats that can be influenced by diet and might affect processes essential to bowel metabolism. Further advances in basic research regarding intestinal inflammation may reveal new insights into the role of inflammatory mediators, referred to as the inflamma-some, and the macromolecular complex of metabolites formed by intestinal bacteria. Collectively, knowledge of the inflamma-some and metagenomics will lead to the development of biomarkers for IBD that target specific pathogenic mechanisms involved in the spontaneous progress of IBD. In this review article, our recent results regarding the discovery of potential proteomic biomarkers using a label-free quantification technique are introduced and on-going projects contributing to either the discrimination of IBD subtypes or to the prediction of cancer risks are accompanied by updated information from IBD biomarker research.

Key words: Inflammatory bowel disease; Biomarker; Proteomics; Tailored medicine; Colitic cancer

Core tip: Our recent achievements in discovering biomarkers to predict cancer risk are introduced. Ultimately, models based on combinations of genotype and gene expression data referenced with clinical, biochemical, and serological data may permit the development of tools for individualized risk stratification and efficient treatment selection, as well as complete rescue from complications, including colitis-associated cancer, in the near future.
INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic inflammatory disease that causes injury to the gastrointestinal (GI) tract and is accompanied by clinical characteristics of remission and relapse. The two common types of IBD are ulcerative colitis (UC) and Crohn’s disease (CD). Although many molecular methods for the investigation of protein and gene sequences have contributed to diagnostic methodologies, the diagnosis of IBD is primarily based on clinical, endoscopic, radiological, and histological criteria. Unfortunately, there has been little to no change in this traditional approach to diagnosis, despite modern advances in genomics and proteomics. However, progress in treatment strategies involving the incorporation of marketed biologicals and molecular targeted therapeutics has lead to the development of the concept of “deep remission” or “mucosal healing” in the treatment of IBD[1,2]. Furthermore, there has been major innovation in diagnostic methods, including the development of more complicated endoscopic and non-invasive imaging methods. These techniques are used to improve quality of life (QOL) of patients, predict complications, and contribute to the prevention or surveillance of cancer associated with IBD such as colitis-associated cancer (CAC)[3].

Recent developments in the molecular pathogenesis of IBD have highlighted three aspects. First, IBD is caused by complex disorders influenced by susceptibility genes, and is characterized by disturbed epithelial barrier function, and abnormal innate and adaptive immunity. Second, the compositions of gut microflora are altered or the epithelial barrier function is disorganized, which leads to a response from the immune system. Third, a murine model has been very helpful in unraveling the pathogenesis/mucosal immunopathology of IBD[4] by suggesting that the abnormal immune reaction to normal microbiota results from dysregulation of the mucosal immune system[5]. For example, the composition of microbes in the gastrointestinal tract may impair the patient’s lifestyle in developed countries and a pathogenic infection in the gastrointestinal tract has a significant function in modulating the immune system. These data may explain why developing and some Asian countries are confronting steep increases in the incidence of IBD. Developments in gene-sequencing technologies, such as next generation sequencing, as well as the emergence of several bioinformatic tools have led to novel insights into the microbe balance in the human gastrointestinal tract and the effect of microbes on human physiology and pathology[6].

Additional innovative technologies, such as mass spectrometry (MS)-based proteomics, also referred to as next generation proteomics, have discovered new classes of proteomic biomarkers that can be used to explore the accurate and comprehensive molecular characterization of IBD genes and proteomes. These advances are expected to lead to more reliable identification of IBD diagnostic- or progression-specific targets and enable molecular diagnosis, as well as provide guidance regarding the selection of treatment options and the risk of cancer development in cases with longstanding remission and relapse[7]. A more robust molecular definition of IBD subtypes is likely to be based on specific molecular pathways that determine not only disease susceptibility, but also disease characteristics, such as location, natural history and therapeutic response. Furthermore, such advances could be applicable in defining “deep remission”, which has not been feasible with currently-used scoring systems or endoscopic evaluation. Discovering biomarkers for IBD may allow objective measurements of disease activity and severity while also serving as prognostic indicators for therapeutic outcomes[8]. Furthermore, the discovery of one or more biomarkers predictive of the risk of IBD-associated cancers, such as CAC, combined with advanced therapeutics, may lead to tremendous improvements in patient QOL in the near future.

In this review article, our recent achievements in discovering biomarkers to predict cancer risk are introduced. Ultimately, models based on combinations of genotype and gene expression data referenced with clinical, biochemical, and serological data may permit the development of tools for individualized risk stratification and efficient treatment selection, as well as complete rescue from complications, including CAC, in the near future[9].

Molecular pathogenesis of colorectal cancer and CAC

Chronic inflammatory diseases are associated with cancer incidence, which is dependent on the duration and severity of the diseases. For example, Barrett’s esophagus is relevant to esophageal cancer, chronic Helicobacter pylori-associated chronic atrophic gastritis is relevant to gastric cancer, and UC or CD are relevant to CAC. These are well-acknowledged examples that support a connection between gut inflammation and cancer. In fact, it has been reported that patients with IBD are at enhanced risk of colorectal cancer (CRC): approximately 15% of CRC patients have related IBD etiology[10]. Although general carcinogenesis is a multi-factorial process that combines accumulation of genetic mutations, post-translational modification, and cell-matrix reciprocal action, inflammation-prone carcinogenesis is somewhat different[11]. The utility of biomarkers for CAC can be extended to permit earlier detection of dysplasia; therefore, the targeted manipulation of biomarkers might lead to advances in cancer therapies and cancer preventions, and may prove to be effective in reducing the development of CAC, with clinical interventions such as blocking agents or...
endoscopic treatments. Regarding molecular aspects, the mechanism of CAC in IBD differs from CRC, which is a well-known adenoma-to-carcinoma sequence. CAC appears to take place from either flat dysplastic tissue or dysplasia-associated lesions or masses\(^\text{[12]}\). The major pathways of sporadic CRC and CAC comprise chromosomal instability, hypermethylation and microsatellite instability; however, CAC shows inflamed colonic mucosa before histological changes of dysplasia or cancer. Patients with IBD have a high risk of CAC following diagnosis, and patients have common symptom, such as colitis\(^\text{[13]}\). The risk of CAC is increased in younger patients, those with more extensive colitis, those with concomitant primary sclerosing cholangitis, and a family history of CRC\(^\text{[14]}\).

Most cancers show no high risk related to proctitis; however, increased in pancolitis, i.e., left-sided colitis, carries an intermediate cancer risk\(^\text{[16]}\). Patients with CD and UD have the same risk of CRC and the prevalence in the US is greater than 200 cases per 100000, representing a total of between 1 and 1.5 million patients with IBD. Fortunately, the incidence of CAC is lower than CRC in the United States and other western countries\(^\text{[16]}\). A biological background for the high risk of CRC in IBD gives a one-sided interpretation, patients with high levels of inflammatory mediators production may progress to CAC. The key signal of IBD-induced carcinogenesis is inflammatory cytokines induced by mucosal and immune cells in the gut. The key molecules of inflammation, including nuclear factor kappaB (NF-κB) and cyclooxygenase-2 (COX-2), are important links between inflammation and cancer. Recently, other factors, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)-induced signaling, have been proven to induce cancer development in animal models of CAC\(^\text{[17]}\). Based on these aspects of molecular carcinogenesis, we have tried to apply biologicals such as infliximab to neutralize TNF-α, a proton pump inhibitor based on mechanisms including the inhibition of NF-κB and tumours as well as attenuation of oxidative stress and aspirin/celecoxib to inhibit cancer-prone COX enzymes. As expected, all of these efforts to block inflammation-promoted carcinogenesis efficiently prevented CAC in our mouse model experiments\(^\text{[18,19]}\). The recent descriptions of epigenetic alterations, in particular alterations in DNA methylation, that have been observed during inflammation and inflammation-associated carcinogenesis, led us to explore nutritional interventions as a means of targeting and correcting epigenetic oncogenic abnormalities, as a form of CAC prevention\(^\text{[20]}\).

**Prediction of CAC**

Patients with long-standing UC and CD are at increased risk of developing CRC, and patients with small intestinal CD have a high risk for developing small bowel adenocarcinoma. Unlike the sporadic CRC that can develop in those with IBD, CAC development is intimately associated with IBD. In those with IBD, CAC results from a process that is believed to begin with mutagenic benign inflammation that develops into indeterminate, low-grade and high-grade dysplasia, and eventually to carcinoma. Regarding the risk factors predisposing to carcinoma in IBD, the risk is increased depending on duration, severity of colitis, presence of sclerosing cholangitis, degree of inflammation and family history of CRC. Evidence-based medicine advises that patients with colitis should be kept under surveillance colonoscopy after diagnosis for 8 to 10 years. As surveillance guidelines for early detection of CAC, the general approach of periodic endoscopic examinations and systematic random biopsies of involved mucosa is generally recommended\(^\text{[21]}\). Recently, advanced colonoendoscopy and confocal microendoscopy, have been used to identify abnormal areas in targeted, but not random, biopsies, and biomarkers could be adopted for high resolution endoscopy\(^\text{[22]}\). Although medications such as aminosalicylates, folate acid and ursodeoxycholic acid seem to be chemopreventive, potent preventive therapeutics, as well as surveillance of high risk patients through the use of potential biomarkers, would seem to be ideal\(^\text{[23]}\).

**Current Status Of Biological Markers For IBD**

Serological markers for IBD are rapidly developing. However, the most studied antibodies, anti-\textit{Saccharomyces cerevisiae} antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA), have limited sensitivity. Thus, the relationship between serological markers of disease pattern and phenotype may be of greater value than the use of serological markers as diagnostic tools. For example, patients with CD who have high titers of various serological makers have more serious small intestine disease than those with low titers of antibodies\(^\text{[24]}\). On the genetic level, application of a genome wide association study design in CD has provided new insights into the immunopathogenesis of CD, identifying links to genes of the innate and adaptive immune system\(^\text{[25]}\). One patient had CD associated with gene mutations of NOD2 and the AT1G161L1 autophagy gene, both of which affect the intracellular processing of bacterial components. In addition, genetic variation of the IL-23 receptor, \textit{STAT3} and \textit{NKK2}-3 genes, were associated with CD and UC in Asian patients. Although comparative analyses of gene associations between CD and UD can identify unique mechanisms of immunopathogenesis of IBD, such results have limited applicability in real-world clinical settings because of ethnic, racial, and environmental differences in the samples studied. Since the advent of the concept of proteomics, a plethora of proteomic technologies have been developed to study proteomes. In IBD, several studies have used proteomics to better understand the disease and discover molecules that could serve as therapeutic targets. The advance of proteomic technologies will have an important effect on the development of new biomarkers for IBD\(^\text{[26]}\). Further advances in proteomic technologies have allowed us to use label-free quantification to detect biomarkers in various IBD patients for the first time. The results are
expected to provide additional insights in to the molecular biomarkers of IBD that may be used in predicting responses to treatment[27].

Classic serological and fecal markers in IBD
Currently, diagnosis of IBD from the blood and stool of patients represent reliable and quantitative tools to clinicians[28]. The C-reactive protein (CRP) and fecal-based leukocyte markers, calprotectin (Cal) or lactoferin (Lf), can help clinicians to assess disease activity and to distinguish IBD from non-inflammatory diarrhea and simple colitis. Serological tests including both ASCA and P-ANCA can be used to determine the current status and risk of IBD[29]. The progression of IBD and inflammatory processes are assessed by tests for CRP and the erythrocyte sedimentation rate (ESR). In addition, clinicians might measure the levels of drug metabolites and antibodies against therapeutic agents that aim to determine why patients do not respond to treatment and to select alternative therapy. The advantages of using the fecal markers including, Cal or Lf, are their ease of detection and use of an inexpensive ELISA technique, as well as their long-term stability in feces[30]. However, several limitations have been associated with these classical serological and fecal markers in IBD. The ESR technique is simple to perform, widely available, and inexpensive; however, it has several disadvantages, such as a concentration that depends on age, several confounders, and the use of certain drugs[31]. Several factors can affect the utility of CRP, including long half-life and prolonged latency period after changes in chronic IBD. Determination of fecal Cal or Lf markers is very helpful into diagnosis chronic IBD, while other GI diseases, ischemic colitis, and non-steroidal anti-inflammatory drug-associated intestinal damage show greater leukocyte elimination in feces[32]. In spite of 80%-100% diagnostic accuracy levels, fecal markers are not specific for IBD and may be elevated in a range of organic conditions. To compensate for these limitations, Langhorst et al[33] evaluated fecal levels of PMN-elastase (PMN-e) in addition to the aforementioned markers and concluded the IBD and IBS can be discriminated by the fecal markers Cal, Lf, and PMN-e. However, these fecal markers have shown a similar capacity to indicate endoscopic pathology, and are more efficient for diagnosis than CRP. Therefore, the combined diagnosis using fecal markers and CRP with disease-specific activity index will be very useful when assessing endoscopic inflammation in UC. It should be noted that these fecal markers were proven to be very efficient in diagnosing IBD as well as in predicting impending clinical relapse in pediatric patients with IBD[34]. Despite the benefits that can be derived from these serum and fecal biomarkers, there remains considerable room for improvement regarding disease prediction and prognosis assessment, as none of them can be applied to predict future risk of CAC development in IBD.

Proteomic markers in IBD
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) and surface-enhanced laser desorption/ionization (SELDI)-TOF MS, have become popular methods recently for the analysis of macromolecules of biological origin such as tissues, serum, or plasma[35]. MALDI-TOF MS is used in clinical medicine to identify disease markers in combination with classic protein gel analysis (1-D) and two dimensional gel electrophoresis separation, accomplished through either peptide mass fingerprinting or peptide sequence tag (2-D) analysis followed by a data base search using proteome blot analysis software[36]. Using these applications, evaluation of samples by MALDI-TOF MS can give novel data regarding peptides present at high molecular mass and may therefore be valuable to assess potential disease markers of IBD. For example, Nanni et al[37] determined serum proteins of 22 healthy subjects and 41 patients with IBD (15 CD, 26 UC) extracted with reversed-phase (C18) and subsequently performed MALDI-TOF MS. The results of serum protein profiles showed the highest overall prognosis capability (96.9%) of identifiable protein biomarkers involved in IBD discrimination. Similarly, in a study by Liu et al[38], serum proteins from 74 CRC samples compared with 48 healthy samples were applied to SELDI-TOF MS using a ProteinChip reader. The diagnostic pattern could distinguish samples according to status of CRC from normal samples with sensitivity and specificity of 95% by independent analysis of the samples. These two studies demonstrated the high potential for biomarker discovery in patients with IBD or CRC in clinical settings, and further clinical validation in large patient cohorts is expected to promote the use of novel biomarkers in clinical practice[39]. In addition to protein identification, 2-D difference gel electrophoresis (2D DIGE) is good method protein quantification; however, isobaric tags for relative and absolute quantification (iTRAQ) and stable isotope labeling by amino acids (SI-LAC) are the best methods developed recently. Sample preparation is important to the success or failure of such analysis and subcellular fractionation can be used to give more specific protein localization analysis than total cellular proteins[40-42]. In our recent study[43], we applied advanced technologies such as iTRAQ and SILAC for label-free quantification in samples obtained from a mouse model of UC and CAC to identify potential biomarkers for cancer-prone inflammation in IBD and to evaluate empirical therapeutics.

PROTEOMIC BIOMARKER DISCOVERY
FOR CAC: A CLASSICAL PROTEOMIC APPROACH
Multiple chemical and biological systems, including intestinal tissue, its associated immune system, the gut microbiota, xenobiotics, and their metabolites, meet and interact to form a tightly regulated state of tissue homeostasis. Disturbance to this state of homeostasis can cause IBD as well as CAC through intercalated multi-factorial
mechanisms. Many strong pathological and mechanistic correlatives exist between mouse models of CAC and the clinically relevant situation in humans, allowing for the use of systems biology approaches\cite{46}. Furthermore, the close proximity of colonic tumors to the myriad of intestinal microbes, as well as the instrumental implication of microbiota in IBD, introduces microbes as new factors capable of triggering inflammation and possibly promoting CAC, necessitating high throughput metabolomic approaches\cite{47}. Additionally, a detailed understanding of these interactions may also provide a means of preventing CAC\cite{48}. In a small study, Watanabe et al\cite{49} performed a low density array analysis of 149 genes implicated in CAC and identified 20 genes showing differential expression between UC- and non-UC-associated CAC, including cancer-related genes such as CYP27B1, runt-related transcription factor 3, sterile alpha motif domain-containing protein 1, EGF-like repeats and discoidin I-like domain 3, nucleolar protein 3, CXCL9, integrin beta2, and LYN. Collier et al\cite{50} demonstrated that 392 transcripts showed differential expression during progression from UC to CAC. Both dysplasia and CAC showed 224 transcripts in common and it was concluded that some genes showed same modification both in dysplasia and CAC, signifying that they might be related to tumor initiation and progression. Following these studies, a host of potential biomarkers have been reported in the literature, including cytokeratin 7/20\cite{51}, a-methylacyl-CoA-racemase\cite{52}, transgelin, a frame shift mutation in the TGF-β type II receptor\cite{53}, HSP47\cite{54}, methylation of the estrogen receptor\cite{55}, association with certain HLA class II alleles\cite{56}, DNA methyltransferase-1\cite{57}, 8-nitroguanine or 8-oxo-deoxyguanine\cite{58,59}, CCL20\cite{60} and activation-induced cytidine deaminase\cite{61}. We used our experimental animal model for colitic cancer, which was provoked with repeated bouts of UC, and an additional proteomic method based on 2-D electrophoresis and MALDI-TOF MS to analyze proteins related in CAC. In detail, 38 proteins were differentially expressed between CAC and healthy samples, using comparative 2-D electrophoresis analysis. Through validation studies, 27 proteins, including enolase, GRP94, HSC70 prohibitin and transgelin, were identified. Among these identified proteins, the downregulation of transgelin in mouse colitic cancer was supported by western blotting and immunohistochemistry. Moreover, transgelin was significantly decreased in colon tumors compared with non-tumorous regions in humans, implying that reduced levels of transgelin could be a good biomarker for CAC\cite{62,63}.

BIOMARKER DISCOVERY FOR CAC: THE NEXT GENERATION OF PROTEOMICS

Currently, knowledge of proteomics is important and provides research with complicated label and label-free techniques. This next generation of proteomics may provide effective perspectives in the diagnosis and treatment of gastrointestinal disease and allow for translation of proteomics from the bench to the bedside. Currently, proteomic studies focus not only in the identification of proteins in a sample, but also the quantification of them. Various protein expression profiles are examined because they provide useful information, especially in clinical proteomics, involving molecular targets related to specific diseases. The technology for proteomics study is continuously developing, and both of labeled and label-free methods have their several advantages. Currently, label-free and isotope-label techniques are used to study proteins quantitatively. The label-free approach, combining spectral and signal quantitation, for identifying amino acids provides accurate relative protein expression data and is an easy way to determine quantitative information. However, this strategy is subject errors from variation in protein preparation that may be reduced when various stable isotopes are inserted in the specimens to make protein isotopomers, which have different spectra according to their different masses. Therefore, several metabolic labeling strategies that apply stable isotopes to minimize error have been developed recently and have been applied in animal models.

Biomarkers to predict CAC risk discovered via label-free quantification analyses

A comparative label-free quantification analysis was conducted in eight patients with UC, eight patients with CD and eight patients with irritable bowel syndrome (IBS). Colonic tissue biopsies were obtained during colonoscopy after written consent and stored in a deep freeze until the assay. Using an Agilent HPLC-Chip 6520 Q-TOF MS system and a label-free quantitative technique (IDEAL-Q v1.0.6.3), signal pathway analysis associated with carcinogenesis was conducted to discover potential biomarkers in CAC (Figure 1). The analysis was conducted according to the degree of intestinal inflammation, type of IBD, and extent of inflammation. To compare against the analysis from IBS samples, the proteins implying CAC risk were isolated (Figure 2A and B). As seen in Figure 2A, 22 significant proteins were found to be potential biomarkers predicting CAC risk in patients with UC. Figure 2B shows the 19 proteins found to be potential biomarkers for CAC risk in patients with CD. Further analysis yielded four important protein biomarkers: proteoglycan 2 (PRG2), S100A6 (calcyclin), ribosomal protein L18 (RPL18), UDP-glucose dehydrogenase (UDGDH) as potential target proteins and predictive biomarkers for CAC risk in IBD (Figure 3). PRG is a major component of the animal extracellular matrix and has been shown to be involved in the differentiation process across the epithelial-mesenchymal axis. It is a potential biomarker inferred principally through its ability to bind growth factors and modulate their downstream signaling; malignant tumors have their individual characteristic PRG profiles closely associated with their differentiation and biological behavior. PRG2 has further been implicated as a biomarker for neuropathic pain attributable to advanced pancreatic cancer in an animal model of CAC\cite{64}, and as an inflammation related gene of several cancers, including prostate,
Park JM et al. Proteomic biomarkers for colitis-associated cancer

Figure 1  Schematic presentation showing proteome analysis to discover potential biomarkers and label-free quantification analysis in inflammatory bowel disease. A: Applying the label-free quantification method to discover proteomic biomarkers in patients with different types and different stage of inflammatory bowel disease (IBD). Comparative analysis was done in eight patients with ulcerative colitis (UC), eight patients with Crohn’s disease (CD) and eight patients with irritable bowel syndrome (IBS). Biopsied colon tissues were obtained during colonoscopy after written consent, and stored in a deep freeze until assayed. Using Agilent HPLC-Chip 6520 Q-time-of-flight mass spectrometry (TOF-MS) and label-free quantitative proteome analysis (IDEAL-Q v1.0.6.3), significant signal pathway analysis was done. In the current review, the analysis done according to the degree of intestinal inflammation, type of IBD, and extent of inflammation from 24 patients, eight from non-IBD normal patients; i.e., IBS patients, eight from patients with UC, and from patients with CD; B: Label-free protein quantification scheme for potential biomarker for colitis-associated cancer (CAC) risk in 16 patients with IBD.
lung, CRC\textsuperscript{[64]} and pancreatic cancer\textsuperscript{[65]}. The expression of S100 calcium binding protein A6 (S100A6) is upregulated in proliferating and differentiating cells\textsuperscript{[66]}, and has been reported to be a possible biomarker for hepatocellular carcinoma\textsuperscript{[67,68]}, pancreatic cancer\textsuperscript{[69]}, acute lymphoblastic leukemia\textsuperscript{[70]}, CRC\textsuperscript{[71]} and breast cancer\textsuperscript{[72]}. RPL18 is a 60S ribosomal protein expressed in stem cells\textsuperscript{[73]} and during adipogenesis\textsuperscript{[74]}. UGDH has been suggested as biomarker for cancer metabolism. The oxidation of UDP-glucose is catalyzed by UGDH to generate UDP-glucuronic acid (UDP-GlcA), a precursor of glycosaminoglycans (GAGs). Wang et al\textsuperscript{[75]} showed decreases in the expressions of UGDH, UDP-GlcA and GAG expression after treatment with a UGDH-siRNA in HCT-8 colon cancer cells and concluded that UGDH could be a new target for CRC clinical treatment\textsuperscript{[76]}. Additionally, UGDH has been identified as a potential biomarker for prostate cancer\textsuperscript{[77,78]}, hepatocellular carcinoma\textsuperscript{[79]} and breast cancer\textsuperscript{[80]}.\par

**Biomarkers to predict CAC risk discovered via label-based protein quantification analyses**

Proteomic techniques with blood and biopsy provide reliable and accurate tools that provide support to clinicians in the diagnosis and treatment of IBD. For example, clinically meaningful biomarkers may be used in the differential diagnosis of CD and UC, or as predictors of treatment responses. Tandem mass spectrometry (MS/MS) is commonly used proteomic analysis. However, various workflows are possible for peptide analysis before MS/MS, as well as bioinformatics, to identify peptides, for which 2-D electrophoresis and subsequent MS, liquid chromatography-MS, 2D DIGE, and iTRAQ are under development. In our previous publication\textsuperscript{[43]}, the present status and perspectives regarding these developed proteomic methods were discussed, with descriptions of examples of new biomarkers for the diagnosis, treatment and prognosis of IBD and CAC in mouse models and in humans. In detail, we showed new concepts and technologies of proteomics, such as protein identification and proteome coverage, as determined by iTRAQ with different shotgun proteomic methods in samples from an animal model of CAC that used repeated oral administration of dextran sulfate sodium (DSS) to induce CAC. As previously reported, iTRAQ protein quantification analysis identified fibronogen beta, prohibitin, transgelin, Hsc-70-interacting protein, suppression of tumorigenicity 13

![Figure 2: Potential proteomic markers signifying colitis-associated cancer risks in inflammatory bowel disease.](image-url)
(ST13), a TKI kinase of the MLK family, dual leucine zipper kinase (MKL1), actin, beta, protein-coding gene (ACTB), ubiquitin carboxyl-term, esterase L3 (UCHL3), coronin, actin binding protein, 1A (CORO1A), hypoxanthine-guanine phosphoribosyltransferase (HPRT), glutathione peroxidase 1 (GPX1), estrogen receptor 1 (ESR1), transcriptional repressor protein 1 (YY1), transcription activator 1, ATP-dependent helicase SMARCA4 (BRG1), braham gene (BRM) and ornithine aminotransferase (OAT) as potential biomarkers for CAC in the DSS-induced colitic cancer model [43].

CONCLUSION

MALDI imaging mass spectrometry (IMS) is a new technology to analyze small peptides in various samples and is a novel tool for studying molecular mechanisms in biological tissues. Recent studies have demonstrated considerable diagnostic and prognostic value, which should be applicable to clinical settings in the near future [81,82]. However, one challenge associated with the use of MALDI-IMS in the identification of potential biomarkers involves the systematic identification of peptides introduced in the MALDI matrix with association of top-down and bottom-up analysis [83]. IMS will be investigated without target-specific reagents to identify new markers for the diagnosis, treatment, and prognosis of CAC, as well as the determination of effective therapies. In the near future, an era of tailored medicine will provide for diagnostic algorithms that include molecular parameters for the detection of early disease and treatment algorithms guided by predicting the individual course of the disease. However, more trials focused on discovering proteomic biomarkers will be necessary to guide the treatment of IBD with more advanced levels of biologicals or molecular targeted therapeutics for inflammation. Using label-free quantification methods on biopsied tissue from patients with IBD, four potential biomarkers, PRG2, S100A6 (calcy-
inflammation, DNA methylation and colitis-associated cancer. *Carcinogenesis* 2012; 33: 723-731 [PMID: 22235026 DOI: 10.1093/carcin/bgs006]

Rubin DT, Ulitsky A, Poston J, Day R, Huo D. What is the most effective way to communicate results after endoscopy? *Gastroenterol Endosc* 2007; 16: 108-112 [PMID: 17591482 DOI: 10.1016/j.gascendec.2006.12.056]

Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? *World J Gastroenterol* 2012; 18: 3839-3848 [PMID: 22876036 DOI: 10.3748/wjg.v18.i29.3839]

Ahmadi A, Polyyak S, Draganov PV. Colorectal cancer surveillance in inflammatory bowel disease: the search continues. *World J Gastroenterol* 2009; 15: 61-66 [PMID: 19115469]

Papp M, Norman GL, Altayor J, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? *World J Gastroenterol* 2007; 13: 2028-2036 [PMID: 17465443]

Choj HJ. The genetics and immunopathogenesis of inflammatory bowel disease. *Nat Rev Immunol* 2008; 8: 458-466 [PMID: 18500220 DOI: 10.1038/nri2340]

Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola M, Li X. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. *Inflamm Bowel Dis* 2009; 15: 341-352 [PMID: 18942757 DOI: 10.1002/ibd.20753]

Han NY, Choi W, Park JM, Kim EH, Lee H, Hahm KB. Label-free quantification for discovering novel biomarkers in the diagnosis and assessment of disease activity in inflammatory bowel disease. *J Dig Dis* 2013; 14: 166-174 [PMID: 23520753 DOI: 10.1111/j.1572-0241.2012.12053]

Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. *Gastroenterology* 2011; 140: 1817-1826.e2 [PMID: 21530748 DOI: 10.1015/j.gastro.2010.11.058]

Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. *Transl Res* 2012; 159: 315-325 [PMID: 22424434 DOI: 10.1016/j.trsl.2012.01.001]

Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. *Gastroenterol Clin North Am* 2012; 41: 483-495 [PMID: 22505030 DOI: 10.1016/j.gcan.2012.01.007]

Gisbert JP, González-Lama Y, Mate J. [Role of biological markers in inflammatory bowel disease]. *Gastroenterol Hepatol* 2007; 30: 117-129 [PMID: 17734234]

Langhorne J, Boone J. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel disease. *Drugs Today* (Barc) 2012; 48: 149-161 [PMID: 22384454 DOI: 10.1016/j.jt.2012.01.001]

Langhorne J, Eisenbruch S, Koelzer J, Rueffer A, Michelsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. *Am J Gastroenterol* 2008; 103: 162-169 [PMID: 17916018 DOI: 10.1111/j.1572-0241.2007.01556.x]

Walkiewicz D, Welin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. *Inflamm Bowel Dis* 2008; 14: 669-673 [PMID: 18240729 DOI: 10.1002/ibd.20576]

Marvin LF, Roberts MA, Fay LB. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. *Clin Chim Acta* 2003; 337: 11-21 [PMID: 14568176]

Horton GL. The MALDI-TOF mass spectrometric view of the...
plasma proteome and peptide. Clin Chem 2006; 52: 1223-1237 [PMID: 16648781 DOI: 10.1373/dinchem.2006.069252]

37 Nanni P, Parisi D, Roda G, Casale M, Belluzzi A, Roda E, Mayer L, Roda A. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom 2007; 21: 4142-4148 [PMID: 18029963 DOI: 10.1002/rcm.3323]

38 Liu XP, Shen J, Li ZF, Yan L, Gu J. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest 2006; 24: 747-753 [PMID: 17162557 DOI: 10.1080/0735796060136837]

39 Gemoll T, Roblick UJ, Auer G, Jornvall H, Habermann JK. SELDI-TOF serum proteomics and colorectal cancer: a current overview. Arch Physiol Biochem 2010; 116: 188-196 [PMID: 20615064 DOI: 10.3109/13813455.2010.495310]

40 Alex P, Gucek M, Li X. Applications of proteomics in the study of inflammatory bowel diseases: Current status and future directions with available technologies. Inflamm Bowel Dis 2009; 15: 616-629 [PMID: 18844215 DOI: 10.1002/ibd.20652]

41 Brewis IA, Brennan P. Proteomics technologies for the global identification and quantification of proteins. Adv Protein Chem Struct Biol 2010; 80: 1-44 [PMID: 21109216 DOI: 10.1016/B978-0-12-381264-3.00001-1]

42 Vaiopoulos A, Gazouli M, Theodopoulos G, Zografos G. Current advances in the application of proteomics in inflammatory bowel disease. Dig Dis Sci 2012; 57: 2755-2764 [PMID: 22740064 DOI: 10.1007/s10620-012-2291-4]

43 Han NY, Kim EH, Choi J, Lee H, Hahn K.B. Quantitative proteomic approaches in biomarker discovery of inflammatory bowel disease. J Dig Dis 2012; 13: 497-503 [PMID: 22988922 DOI: 10.1111/j.1751-2780.2012.00625.x]

44 Mangerich A, Dedon PC, Fox JG, Tannenbaum SR, Wogan GN. Chemistry meets biology in colitis-associated carcinogenesis. Free Radic Res 2013; 47: 958-986 [PMID: 23926919 DOI: 10.3109/10571576.2013.822239]

45 Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2013; 35: 229-244 [PMID: 23614455 DOI: 10.1007/s00281-012-0352-6]

46 Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 2009; 6: 297-305 [PMID: 19404270 DOI: 10.1038/nrgastro.2009.44]

47 Watanabe T, Kobunai T, Yamamoto Y, Ikeuchi H, Matsuda I, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, Yokoyama T, Konishi T, Eshima K, Araki T, Tanaka K, Hashimoto K, Okita Y, Fujiwara I, Fujima T, Fujisawa R, Mizumoto K, Nakabeppu Y, Iida M, Yao T, Tsuchiyoshi M. Altered expression of MUTYH and an increase in 8-hydroxydeoxyguanosine are early events in ulcerative colitis-associated colorectal cancer. Gut 2009; 58: 1226-1233 [PMID: 188-196 [PMID: 19603022 DOI: 10.1097/MCG.0b013e31812f5e1]

48 Hashimoto K, Hirahashi M, Matsumoto T, Fujita K, Fujisawa R, Mizumoto K, Nakabeppu Y, Iida M, Yao T, Tsuchiyoshi M. Expression in rectal mucosa with the development of ulcerative colitis-associated neoplasia by nitrative DNA damage marker 8-nitroguanin expression in rectal mucosa. J Clin Gastroenterol 2013; 47: e80-e86 [PMID: 23632356 DOI: 10.1097/MCG.0b013e31828f1302]

49 Ock CH, Kim EH, Choi DJ, Lee HJ, Hahn KB, Chung MH. 8-Hydroxydeoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress-implicated gastrointestinal diseases. World J Gastroenterol 2012; 18: 302-308 [PMID: 22294836 DOI: 10.3748/wjg.v18.i4.302]

50 Gushima M, Hirahashi M, Matsumoto T, Fujita K, Ohuchida K, Oda Y, Yao T, Iida M, Tsuneyoshi M. Expression in colorectal cancer. Pathol Int 2009; 59: 460-469 [PMID: 22048860 DOI: 10.1111/j.1527-6937.2010.01351.x]

51 Yeo M, Kim DK, Park HJ, Oh TY, Kim JH, Cho SW, Paik YK, Hahn KB. Loss of transglisin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. Proteomics 2006; 6: 1158-1165 [PMID: 16402363 DOI: 10.1002/pmc.205050390]

52 Demir IE, Schorn S, Schremmer-Danninger E, Wang K, Kehl T, Giese NA, Algti H, Fries H, Ceyhan GO. Perineural cell masses are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. PLoS One 2013; 8: e60529 [PMID: 23559899 DOI: 10.1371/journal.pone.0060529]

53 Meyer TE, Chu LW, Li Q, Yu K, Rosenberg PS, Menashe I, Chokkalingam AP, Quraishi SM, Huang WY, Weiss JM, Kaaks R, Hayes RB, Chanock SJ, Hsing AW. The association between inflammation-related genes and serum androgen levels in men: the prostate, lung, colorectal, and ovarian
study. Prostate 2012; 72: 65-71 [PMID: 21520164 DOI: 10.1002/pros.24107]

Hagihara A, Miyamoto K, Furuta J, Hiraoka N, Wakazono K, Seki S, Fukushima S, Tao S, Sugimoto T, Ushijima T. Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004; 23: 8705-8710 [PMID: 15467763 DOI: 10.1038/sj.onc.1207783]

Nowotny M, Bhattacharya S, Filipcek A, Kreuz AM, Chazin W, Kuznicki J. Characterization of the interaction of calcycin (S100A6) and calcycin-binding protein. J Biol Chem 2000; 275: 31178-31182 [DOI: 10.1074/jbc.M001622200]

Li Z, Tang M, Ling B, Liu S, Zheng Y, Nie C, Yuan Z, Zhou L, Guo G, Tong A, Wei Y. Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma. J Mol Med (Berl) 2014; 92: 291-303 [PMID: 24281831 DOI: 10.1007/s00109-013-1104-3]

Hua Z, Chen J, Sun B, Zhao G, Zhang Y, Fong Y, Jia Z, Yao L. Specific expression of osteopontin and S100A6 in hepatocellular carcinoma. Surgery 2011; 149: 783-791 [PMID: 21301450 DOI: 10.1016/j.surg.2010.12.007]

Zihao G, Jie Z, Yan L, Jing Z, Jing C, Xue L, Jing Z, Heng LW, Ru G, Jianyu H. Analyzing S100A6 expression in endoscopic ultrasonography-guided fine-needle aspiration specimens: a promising diagnostic method of pancreatic cancer. J Clin Gastroenterol 2013; 47: 69-75 [PMID: 22914344 DOI: 10.1097/MCG.0b013e318261752]

Tamai H, Miyake K, Yamaguchi H, Takatori M, Dan K, Inokuchi K, Shimada T. Resistance of MLL-AF11-positive acute lymphoblastic leukemia to tumor necrosis factor-α is mediated by S100A6 upregulation. Blood Cancer J 2011; 1: e38 [PMID: 2292076 DOI: 10.1038/bcj.2011.37]

Kilanczyk E, Graczyk A, Ostrowska H, Lasicka I, Leśniak W, Filipcek A. S100A6 is transcriptionally regulated by β-catenin and interacts with a novel target, lamin A/C, in colorectal cancer. Mol Cell Proteomics 2013; 12: 470-477 [PMID: 23560296 DOI: 10.1074/mc.2012.04.005]

McKerrie E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. Tumour Biol 2011; 32: 441-450 [PMID: 21153724 DOI: 10.1007/s13277-010-0137-2]

Choi WH, Zhou R, Yeo SS, Zhang F, Wang DA. Determination and validation of reference gene stability for qPCR analysis in polysaccharide hydrogel-based 3D chondrocytes and mesenchymal stem cell cultural models. Mol Biotechnol 2013; 54: 623-633 [PMID: 23054629 DOI: 10.1007/s12053-012-9604-x]

Fromm-Dornieden C, von der Heyde S, Lytovchenko O, Saliñas-Riester G, Borejó B, Beissbarth T, Baumgartner BG. Novel polysome messages and changes in translational activity appear after induction of adipogenesis in 3T3-L1 cells. BMC Mol Biol 2012; 13: 9 [PMID: 22486605 DOI: 10.1186/1471-2199-13-9]

Wang TP, Fan YR, Fu CY, Chang HY. Down-regulation of UDP-glucose dehydrogenase affects glycosaminoglycans synthesis and motility in HCT-8 colorectal carcinoma cells. Exp Cell Res 2010; 316: 2893-2902 [PMID: 20691680 DOI: 10.1016/j.yexcr.2010.07.017]

Egger S, Chaikuad A, Kavanagh KL, Oppermann U, Niedetzky B. UDP-glucose dehydrogenase: structure and function of a potential drug target. Biochem Soc Trans 2010; 38: 1378-1385 [PMID: 20963317 DOI: 10.1042/BST0381378]

Huang D, Casale GP, Tian J, Lele SM, Pisarev VM, Simpson MA, Hemstreet GP. UDP-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer. Int J Cancer 2010; 126: 315-327 [PMID: 1967054 DOI: 10.1002/ijc.24820]

Wei Q, Galbenus R, Zaza R, Cerny RL, Simpson MA. Androgen-stimulated UDP-glucose dehydrogenase expression limits prostate androgen availability without impacting hyaluronan levels. Cancer Res 2009; 69: 2332-2339 [PMID: 19244115 DOI: 10.1158/0008-5472.CAN-08-3083]

Fan HZ, Liu H, Zhang C, Gao DM, Xue Q, Chen J, Sun RX, Liu YK, Yang PY. Comparative proteomics and molecular mechanical analysis in CDA-II induced therapy of LCI-D20 hepatocellular carcinoma model. J Cancer Res Clin Oncol 2009; 135: 591-602 [PMID: 18853186 DOI: 10.1007/s00432-008-0493-0]

Huh JW, Choi MM, Yang SJ, Yoon SY, Choi SY, Cho SW. Inhibition of human UDP-glucose dehydrogenase expression using siRNA expression vector in breast cancer cells. Biotechnol Lett 2005; 27: 1229-1232 [PMID: 16158268 DOI: 10.1007/s10529-005-0022-x]

Maier SK, Hahne H, Gholami AM, Balluff B, Meding S, Schoene C, Walch AK, Kuster B. Comprehensive identification of proteins from MALDI imaging. Mol Cell Proteomics 2013; 12: 2901-2910 [PMID: 23782541 DOI: 10.1074/mcp.M113.027599]

Ko KH, Kwon CI, Park SH, Han NY, Lee HK, Kim EH, Hahn KB. Application of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Imaging Mass Spectrometry (MALDI-TOF IMS) for Premalignant Gastrointestinal Lesions. Clin Endosc 2013; 46: 611-619 [PMID: 24340253 DOI: 10.5946/bst.2013.46.6.611]

Schwamborn K, Caprili RM. Molecular imaging by mass spectrometry—looking beyond classical histology. Nat Rev Cancer 2010; 10: 639-646 [PMID: 20720571 DOI: 10.1038/nrc2917]

P-Reviewer: Prasad KK, van Langenberg DR, Vynios D, Voortman J S-Editor: Gou SX L-Editor: Stewart G E-Editor: Wang CH
